Volume 2014, Issue 1
  • E-ISSN: 2223-506X


Most cases of chronic myeloid leukemia (CML) are associated with the presence of fusion gene; a molecular anomaly that introduced targeting therapy to CML. This study was setup primarily to optimize the real-time quantification detection of transcripts, in order to pave the way for using this method as a diagnostic tool to support the clinical management of CML patients in Qatar.

A secondary objective was to evaluate the response of CML patients to Imatinib (IM) and exploit adaption of this technique as an indicator of emerging drug resistance reported in Qatar.

Peripheral blood (PB) samples from 26 CML patients receiving Imatinib, were analysed via serial Real-time quantitative polymerase chain reaction (RT-qPCR) to monitor the ratio of to normal transcripts. EuropeanLeukemia Net (ELN) 2006 and 2009 guidelines were employed to assess the molecular response to Imatinib.

For patients to be classified as optimal responders, major molecular response (MMR) had to be achieved by 18 months of treatment.1 Patients responding to Imatinib achieved major molecular response (MMR) during the 1st year of treatment; while patients who resisted Imatinib treatment did not achieve any molecular response within this time frame.

This was the first molecular study to evaluate the molecular response of CML patients (citizens and residents) to IM in Qatar.


Article metrics loading...

Loading full text...

Full text loading...


Data & Media loading...

  • Article Type: Research Article
Keyword(s): ABL1 , BCR-ABL1 , CML , Imatinib Mesylate (IM) and RT-qPCR
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error